Arvinas (NASDAQ:ARVN) Given New $115.00 Price Target at Cantor Fitzgerald

Arvinas (NASDAQ:ARVNGet Rating) had its target price cut by Cantor Fitzgerald from $140.00 to $115.00 in a research report report published on Friday morning, The Fly reports.

Other equities research analysts have also recently issued research reports about the company. Citigroup dropped their price objective on Arvinas to $103.00 and set a buy rating on the stock in a research note on Friday, May 20th. HC Wainwright decreased their target price on Arvinas from $135.00 to $90.00 and set a buy rating on the stock in a report on Friday. SVB Leerink decreased their target price on Arvinas from $91.00 to $89.00 and set an outperform rating on the stock in a report on Friday. Stifel Europe decreased their target price on Arvinas from $85.00 to $82.00 and set a buy rating on the stock in a report on Thursday, May 5th. Finally, Wedbush lowered Arvinas from an outperform rating to a neutral rating and set a $43.00 target price on the stock. in a report on Monday, May 9th. Three research analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company. According to MarketBeat, Arvinas presently has an average rating of Moderate Buy and an average price target of $86.67.

Arvinas Trading Up 7.8 %

Shares of Arvinas stock opened at $55.43 on Friday. Arvinas has a 12-month low of $34.90 and a 12-month high of $103.53. The business’s 50 day moving average is $46.12 and its 200-day moving average is $56.79.

Arvinas (NASDAQ:ARVNGet Rating) last announced its quarterly earnings data on Thursday, August 4th. The company reported ($1.32) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.04) by ($0.28). Arvinas had a negative return on equity of 30.11% and a negative net margin of 255.97%. The company had revenue of $31.30 million for the quarter, compared to the consensus estimate of $23.71 million. During the same quarter in the prior year, the company earned ($1.03) EPS. The company’s revenue for the quarter was up 469.1% on a year-over-year basis. On average, equities research analysts expect that Arvinas will post -4.36 EPS for the current year.

Institutional Trading of Arvinas

Several large investors have recently modified their holdings of the stock. State Board of Administration of Florida Retirement System grew its holdings in shares of Arvinas by 30.0% during the 2nd quarter. State Board of Administration of Florida Retirement System now owns 22,680 shares of the company’s stock worth $955,000 after purchasing an additional 5,230 shares in the last quarter. M&T Bank Corp lifted its position in shares of Arvinas by 29.4% during the 2nd quarter. M&T Bank Corp now owns 10,560 shares of the company’s stock worth $444,000 after buying an additional 2,398 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. lifted its position in shares of Arvinas by 53.0% during the 2nd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 122,928 shares of the company’s stock worth $5,174,000 after buying an additional 42,578 shares during the last quarter. State of New Jersey Common Pension Fund D lifted its position in shares of Arvinas by 33.9% during the 2nd quarter. State of New Jersey Common Pension Fund D now owns 50,890 shares of the company’s stock worth $2,142,000 after buying an additional 12,876 shares during the last quarter. Finally, Candriam S.C.A. lifted its position in shares of Arvinas by 1.3% during the 2nd quarter. Candriam S.C.A. now owns 496,947 shares of the company’s stock worth $20,915,000 after buying an additional 6,240 shares during the last quarter. 84.52% of the stock is owned by institutional investors and hedge funds.

Arvinas Company Profile

(Get Rating)

Arvinas, Inc, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC); ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer; and ARV-766 an investigational orally bioavailable PROTAC protein degrader for the treatment of men with mCRPC.

See Also

The Fly logo

Analyst Recommendations for Arvinas (NASDAQ:ARVN)

Receive News & Ratings for Arvinas Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arvinas and related companies with MarketBeat.com's FREE daily email newsletter.